Every 8-K that 23andMe Holding Co. (ME) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ME filings page.
Chrome Holding Co., formerly 23andMe Holding Co., has entered a stock purchase agreement to sell its Lemonaid telehealth businesses. A newly formed buyer, Lemonaid SPV, Inc., backed by Bambumeta Ventures, agreed to acquire 100% of the shares of Lemonaid Health Inc. and Chrome Pharmacy Holdings, Inc. for a cash purchase price of $10 million, plus additional cure payments to bring certain assumed contracts current. The buyer has placed a $2.5 million good faith deposit, which will be credited at closing.
The sale is part of the company’s ongoing Chapter 11 process, following an earlier sale of substantially all other assets to 23andMe Research Institute for $302.5 million in cash and assumed liabilities. Closing is subject to several conditions, including confirmation and effectiveness of a Chapter 11 plan and required regulatory approvals. The company reiterates that trading in its Class A common stock is highly speculative, and market prices may bear little or no relationship to any eventual recovery for shareholders in the bankruptcy cases.
Chrome Holding Co., formerly known as 23andMe Holding Co., describes a leadership and compensation update while it remains in Chapter 11 bankruptcy proceedings. The company previously sold substantially all of its assets to 23andMe Research Institute under an Asset Purchase Agreement, and that nonprofit has now appointed Chrome’s interim leader, Joseph Selsavage, as its Chief Financial Officer.
During a defined transition period starting August 21, 2025, Selsavage will serve in a dual role as Chief Executive Officer and Chief Financial and Accounting Officer of Chrome Holding Co. and as Chief Financial Officer of the Research Institute. For his work at Chrome during this time, he will receive 75% of his current annual base salary rate of $600,000. The board’s Special Committee also removed the “Interim” designation from his title, formally naming him Chief Executive Officer and Chief Financial and Accounting Officer.
23andMe Holding Co. (Chrome Holding Co.) filed a Proposed Joint Plan and a Proposed Disclosure Statement in connection with Chapter 11 cases. The Proposed Plan and Disclosure Statement are dated Aug 15, 2025 and describe the Plan, classification of claims and interests, events leading to the Chapter 11 cases, and anticipated case developments including solicitation of creditor and equity-holder votes. The documents have been filed with the court but have not been approved as of the filing. Solicitation of votes will follow applicable law and court orders. The Debtors provide access to the Proposed Plan, Proposed Disclosure Statement, and other case materials on Kroll at https://restructuring.ra.kroll.com/23andMe. The Current Report notes a signature by Joseph Selsavage as Interim Chief Executive Officer and Chief Financial and Accounting Officer dated Aug 18, 2025.
Chrome Holding Co., formerly known as 23andMe Holding Co., has officially changed its corporate name. Effective August 14, 2025, the company filed a certificate of amendment to its Certificate of Incorporation in Delaware to change its name from “23andMe Holding Co.” to “Chrome Holding Co.”
The company states that this name change does not affect the rights of its stockholders and that no other changes were made to its Certificate of Incorporation. The amendment itself is included as an exhibit to the report for reference.
23andMe Holding Co. (ME) receives Bankruptcy Court approval to sell substantially all assets. On 27 June 2025, the U.S. Bankruptcy Court for the Eastern District of Missouri entered an order authorizing the Debtors to consummate the previously announced Asset Purchase Agreement with TTAM Research Institute, a California non-profit affiliated with co-founder Anne Wojcicki.
Transaction terms: TTAM will purchase virtually all assets—excluding Lemonaid Health’s tele-health operations—for $305.0 million in cash and will assume specified liabilities. TTAM will also act as stalking-horse sponsor to acquire the excluded Lemonaid business for $2.5 million.
Key timeline:
- Chapter 11 petitions filed: 23 March 2025
- Asset Purchase Agreement executed: 13 June 2025
- Court approval of sale: 27 June 2025
- Press release issued: 30 June 2025 (Exhibit 99.1)
The Company reiterates that trading in Class A common stock is highly speculative; market prices may not correspond to any ultimate recovery. No pro-forma financials or creditor recovery estimates were included in this Form 8-K. Stakeholders can access additional documents via Kroll’s restructuring website or hotline.